Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL

Clinical trial NCT03367143 · UNKNOWN

Trial details

NCT number: NCT03367143
Sponsor: Ruijin Hospital
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Diffuse Large B-Cell Lymphoma Refractory

Start date: 2016-12-01
Primary completion: 2020-12-01
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.